World DNA Probes-based Diagnostics Market

World DNA Probes-based Diagnostics Market

This report analyzes the worldwide markets for DNA Probes-based Diagnostics in Millions of US$. The specific end-use segments discussed are Infectious Diseases, Cancer Testing, Genetic Predisposition, Identity/Forensics, Molecular HLA (Human Leukocyte Antigen) Typing, and Others. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Latin America. Annual forecasts are provided for each region for the period of 2000 through 2015. The report profiles 65 companies including many key and niche players worldwide such as Abbott Laboratories, Affymetrix Inc., Becton Dickinson & Company, Beckman Coulter, Inc., bioMerieux, Celera Group, Gen-Probe Incorporated, Genzyme Corporation, Luminex Molecular Diagnostics, QIAGEN, Roche Diagnostics, and Siemens Healthcare Diagnostics, Inc., Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

DNA PROBES-BASED DIAGNOSTICS MCP-3405
A GLOBAL STRATEGIC BUSINESS REPORT


CONTENTS


I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations I-1
Disclaimers I-2
Data Interpretation & Reporting Level I-2
Quantitative Techniques & Analytics I-3
Product Definitions and Scope of Study I-3
Infectious Diseases I-3
Cancer I-4
Genetic Predisposition I-4
Identity/Forensics I-4
Molecular HLA Testing I-4
Other Diagnostic Applications I-4


II. EXECUTIVE SUMMARY

1. Market Dynamics II-1
Industry Overview II-1
DNA Probes: Robust Growth Ahead II-1
Decoding the Genetic Puzzle II-1
Advantages of DNA-Probe Tests II-2
Growth Drivers in a Nutshell II-2
Growth Inhibitors in a Nutshell II-2
Genetic Profiling of Pathogens: A Road Less Traveled II-3
Roche’s Entry into the Hall of Molecular Fame II-3
DNA Technology: An Evolutionary Scan II-3
An Era of Excellence: Tracking Landmark Breakthroughs in
DNA Diagnostics II-4
Opportunities II-5
Market Trends/Issues II-5
DNA Tests: Finding Use in Numerous Applications II-5
World’s Aging Population Drives the Popularity of DNA-Probe
Tests II-6
Reimbursements: “Under the Umbrella” II-6
Evolution of New & Virulent Infectious Agents II-6
The Enlightened Consumer of the 21st Century II-6
Challenges In Widespread Deployment of DNA Based Diagnostics II-7
Miniaturization: An Uphill Task II-7
Improvements in Assay Capabilities II-7
Information Handling & Processing: The Soft Side of
Diagnostics II-8
Integration: The Ultimate Challenge II-8
United States: Unraveling the Country’s Edge in DNA based
Diagnostics II-8

2. DNA Probes-Based Diagnostics - A Primer II-9
Diagnostic Gene Detection Products II-9
Molecular Diagnostics: A Powerful Disease Detection Tool II-9
DNA Probes-Based Products II-10
Direct Detection of Target Sequence II-10
Nucleic Acid Amplification II-10
Gene Detection Using DNA Chips II-10
Gene Detection by DNA Sequencing II-10
The Dynamics of Key Enabling Technologies II-11
In Situ Hybridization II-11
PCR: Polymerase Chain Reaction II-11
Chemiluminescence II-11
Gen-Probe Tigris II-12
DNA Chips II-12
Key Players II-12
Players in Molecular Diagnostics Market II-12
Molecular Diagnostics - A Primer II-12
Implications for Clinical Diagnostics II-13
Need of the Hour II-13
Molecular Diagnostics: Marking the Convergence of Numerous
Technologies II-13
Impact of the Human Genome Project II-13
Molecular Diagnostics: Domain of the Developed Countries II-14
“Tailored Patient Management”: An Epitomized Future of
Molecular Diagnostics II-14
Futuristics: A Rumination II-14

3. Product Overview II-15
Background II-15
Gene Probe Technology II-15
What is DNA? II-15
DNA Probes II-15
Miniaturization: A Revolutionary Method in DNA Analysis II-16
Gene Chip Technology II-16
DNA Chips II-16
Chromosome Painting Probes II-16
Diagnostic Applications Based on DNA Probes: An Overview II-16
Infectious Diseases II-16
Respiratory Tract Infections II-17
Diagnosis of Mycoplasma II-17
DNA Probes to Detect Legionella Pneumophila II-17
Detecting Tuberculosis Through Rapid Diagnostic Tests II-17
How the Technique Works II-17
Limitations II-18
Sexually Transmitted Diseases (STDs) II-18
HIV II-18
HTLV-1 Testing II-18
Hepatitis Testing II-18
Chlamydia DNA Probes II-18
Detection of Intestinal Parasites II-18
Entamoeba Histolytica II-18
Salmonella II-19
Identity/Forensics II-19
DNA Profiling: A Key Forensic Tool II-19
DNA-Based Forensic Diagnostics II-19
Tracing Human Origins II-20
Genetic Predisposition II-20
Molecular HLA Testing II-20
Human Leukocyte Antigen (HLA) Typing II-20
Cancer Testing II-20
Cancer: A Deadly Disease Afflicting Millions II-20
Slow Detoxifiers: Potential Cancer Candidates II-20
Improving Cancer Surgery Through Diagnostic Tests II-21
Types of Cancer II-21
Chronic Lymphocytic Leukemia (CLL) II-21
Breast Cancer II-21
PCR Screening Technology for Breast Cancer II-21
Eye Cancers II-21
DNA Probes to Detect Retinoblastoma II-21
Others II-22
The Ames test II-22
Genetic Testing II-22
Other Diagnostic Applications II-22
Cystic Fibrosis II-23
Malaria Testing II-23
Detection of Multidrug Resistance II-23
Bacterial Resistance to Antibiotics II-23
DNA Probes for Agriculture II-23

4. Product Innovations/Introductions II-24
Luminex Molecular Introduces New xTAG™ Respiratory Viral Panel II-24
Gen-Probe Introduces Aptima HPV Assay in Europe II-24
Genzyme Genetics Introduces Prenatal Diagnosis and Carrier
Testing II-24
Affymetrix Launches New Cytogenetic Solution II-25
Genekam Biotech Develops New Commercial DNA-Test to Detect
Bird Flu II-25
Seegene Launches Innovative DNA Test to Detect HPVs II-25
deCODE Introduces deCODE T2 II-26
InterGenetics Introduces OncoVue II-26
bioMérieux Unveils VIDAS C II-26
bioMérieux Unveils NucliSENS EasyQ HPV II-26
Applied Biosystems Launches SOLiD System II-27
bioMérieux Introduces VIDAS® NT-proBNP II-27
Abbott Molecular Rolls Out Six DNA Probes II-27
PerkinElmer Launches Two New Multiplexing Platforms for
Genomic Research II-28
Kreatech Introduces First Complete Whole Genome Amplification
Kit II-28
Relative Genetics Introduces DNA Testing Services II-29
Sorenson Launches Over-the-counter Paternity Test Kits II-29
Kimball Genetics Introduces Warfarin Sensitivity DNA Test II-29
bioMérieux Introduces TEMPO EB II-29
Gen-Probe Launches PCA3 Assay II-30
Genzyme Launches New KRAS Mutation Analysis II-30
BD Launches New BD Viper™ System for Automating Molecular
Diagnostic Testing Process II-30
Affymetrix Unveils New GeneChip® Scanner with Higher Capacity
Scanning II-30
Genzyme Introduces EGFR Mutation Assay for Detecting Mutations II-31
bioMérieux Rolls Out FoodExpert-ID Molecular Multi-Detection
Test for Feed Analysis II-31

5. Recent Industry Activity II-32
Genzyme Enters into Licensing Agreement with Moffitt Cancer
Center II-32
Xceed Molecular Offers Gen-Probe License for Flow-Thru Chip®
Technology II-32
Dako Denmark’s TOP2A FISH pharmDx Receives FDA Approval II-32
Roche Diagnostics Receives Approval for Elecsys Anti-HCV Assay II-32
bioMérieux and FIND Ink Memorandum of Understanding II-33
BD Establishes Second Production Facility in China II-33
Shanghai Kehua Bio-engineering and bioMérieux Establish Joint
Venture II-33
Quidel to Enter into Alliance with bioMérieux II-34
Beckman Coulter Bags Rights to Hepatitis C Virus Test from
Siemens II-34
Affymetrix Enters into Partnership with Pathwork Diagnostics II-34
Luminex Signs Distribution and Sales Agreement with Abbott II-35
Gen-Probe to Acquire Innogenetics II-35
Biocept to Introduce I.D.Rh(D) II-36
DNA Testing Systems and DNAPrint Genomics Sign Sales Agreement II-36
Siemens Acquires Dade Behring II-36
Sorenson Genomics Acquires Identigene II-37
BioServe Takes Over Genomics Collaborative II-37
Illumina Acquires Solexa II-37
QIAGEN to Merge With eGene II-38
NorDiag Acquires Genpoint II-38
Cepheid Takes Over Sangtec Molecular Diagnostics II-38
3M Enters into Collaboration with Gen-Probe II-38
Luminex Corporation Completes Acquisition of Tm Bioscience II-39
Ventana Medical Systems and C-Path to Collaborate with NCI
and FDA II-39
Ipsen and bioMérieux Enter into Theragnostics Agreement II-40
Celera Acquires Atria Genetics II-40
Celera Acquires Berkeley HeartLab II-41
Beckman Coulter Enters into Partnership II-41
Affymetrix Partners with IPSOGEN for In-Vitro Diagnostic
Cancer Testing II-41
Ventana Medical Systems Collaborates with Genentech II-42
Siemens Medical Solutions Acquires Bayer’s Diagnostic Division II-42
Orchid Cellmark Acquires ReliaGene Technologies II-42
GATC Enters into Collaboration for Developing DNA-based
Diagnostic Test II-42
Genetic Solutions and Catapult Merge to Establish Catapult
Genetics II-43
Grant Life Sciences Signs MoU with Alphagenics Diaco
Biotechnologies II-43
Gen-Probe and Millipore Ink Agreement to Market MTC-NI Test II-44
QIAGEN Acquires Digene Corporation II-44
BD Diagnostics and Quest Diagnostics Sign Agreement for BD
Viper™ System II-45
Enzo Biochem Plans to Produce Single Copy DNA Probes II-45
Affymetrix Signs Two Agreements with Sysmex II-45
Affymetrix and Partners HealthCare Enter into Collaboration II-46
Affymetrix and Epigenomics Enter into an Agreement II-46
Roche Introduces Elecsys TORCH Assays II-47
QIAGEN to Take Over Gentra II-47
LGC Acquires AGOWA to Extend German Operations II-47
ENZ Receives Patent for Phosphate Labeling for Medical
Research & DNA Diagnostic Products II-47
TMC Achieves CE Mark for its Tag-It Cystic Fibrosis Test Kit II-48
Toshiba Licenses Electrochemical Detection Technology to Antara II-48
Affymetrix Licenses Multiple Patents to Invitrogen II-48
Abbott Enters into Agreement with ALSI for Licensing ProGRP
Biomarker II-49
QIAGEN in Protein Crystallography Co-Marketing Agreement with
ActiveSight II-49
Warnex Acquires Pro-DNA Diagnostic II-49
Celera Genomics Gains Complete Ownership of Celera Diagnostics II-50
Gen-Probe Licenses Exclusive Rights for Diagnostic Tests
Development from University of Michigan II-50
QIAGEN Enters into Licensing Agreement with Applied Biosystems
for Real-Time PCR Technologies II-50
IGC Collaborates with Roche for Cancer Biomarker Discovery II-51
Affymetrix Acquires ParAllele BioScience II-51
QIAGEN Enters into Distribution Agreement with Osmetech
Molecular Diagnostics II-51
GlaxoSmithKline Acquires Canada-Based ID Biomedical Corp. II-51
Gen-Probe Obtains FDA Approval for APTIMA II-52
Gen-Probe Signs Purchasing Agreement with Roche II-52
MP Biomedicals Acquires Qbiogene II-52
Roche Diagnostics Receives FDA Approval for AmpliChip CYP450 Test II-52
Ventana Launches ISH Tests II-52
Abbott Receives FDA Approval for Use of AutoVysion™ System II-52
Affymetrix Opts Veridex for its GeneChip® Technology II-53
Abbott Signs Distribution Agreement with BioGenex II-53

6. Focus on Select Players II-54
Abbott Laboratories (US) II-54
Affymetrix Inc (US) II-54
Becton Dickinson & Company (US) II-54
Beckman Coulter, Inc. (US) II-55
bioMérieux (France) II-55
Celera Group (US) II-55
Gen-Probe Incorporated (US) II-55
Genzyme Corporation (US) II-56
Luminex Molecular Diagnostics (Canada) II-56
QIAGEN (US) II-56
Roche Diagnostics (Switzerland) II-56
Siemens Healthcare Diagnostics, Inc. (US) II-56

7. Global Market Perspective II-57
Table 1: World Recent Past Current & Future Analysis for DNA
Probes-based Diagnostics by Geographic Region- US, Canada,
Japan, Europe, Asia–Pacific (excluding Japan) and Latin
America Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2000 through 2010 (includes
corresponding Graph/Chart) II-57

Table 2: World Long-term Projections for DNA Probes-based
Diagnostics by Geographic Region – US, Canada, Japan, Europe,
Asia-Pacific (excluding Japan), and Latin America Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2011 through 2015 (includes corresponding
Graph/Chart) II-58

Table 3: World 10-Year Perspective for DNA Probes-based
Diagnostics by Geographic Region- Percentage Breakdown of
Dollar Sales for US, Canada, Japan, Europe, Asia–Pacific
(excluding Japan) and Latin America for Years 2003, 2008 &
2012 (includes corresponding Graph/Chart) II-59

Table 4: World Recent Past Current & Future Analysis for DNA
Probes-based Diagnostics (Infectious Disease Diagnosis) by
Geographic Region- US, Canada, Japan, Europe, Asia–Pacific
(excluding Japan) and Latin America Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2000 through 2010 (includes corresponding Graph/Chart) II-60

Table 5: World Long-term Projections for DNA Probes-based
Diagnostics (Infectious Disease Diagnosis) by Geographic
Region – US, Canada, Japan, Europe, Asia-Pacific (excluding
Japan), and Latin America Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2011 through
2015 (includes corresponding Graph/Chart) II-61

Table 6: World 10-Year Perspective for DNA Probes-based
Diagnostics (Infectious Disease Diagnosis) by Geographic
Region- Percentage Breakdown of Dollar Sales for US, Canada,
Japan, Europe, Asia–Pacific (excluding Japan) and Latin
America for Years 2003, 2008 & 2012 (includes corresponding
Graph/Chart) II-62

Table 7: World Recent Past Current & Future Analysis for DNA
Probes-based Diagnostics (Cancer Diagnosis) by Geographic
Region- US, Canada, Japan, Europe, Asia–Pacific (excluding
Japan) and Latin America Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2000 through
2010 (includes corresponding Graph/Chart) II-63

Table 8: World Long-term Projections for DNA Probes-based
Diagnostics (Cancer Diagnosis) by Geographic Region – US,
Canada, Japan, Europe, Asia-Pacific (excluding Japan), and
Latin America Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2011 through 2015 (includes
corresponding Graph/Chart) II-64

Table 9: World 10-Year Perspective for DNA Probes-based
Diagnostics (Cancer Diagnosis) by Geographic Region-
Percentage Breakdown of Dollar Sales for US, Canada, Japan,
Europe, Asia–Pacific (excluding Japan) and Latin America for
Years 2003, 2008 & 2012 (includes corresponding Graph/Chart) II-65

Table 10: World Recent Past Current & Future Analysis for DNA
Probes-based Diagnostics (Genetic Predisposition Diagnosis) by
Geographic Region- US, Canada, Japan, Europe, Asia–Pacific
(excluding Japan) and Latin America Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2000 through 2010 (includes corresponding Graph/Chart) II-66

Table 11: World Long-term Projections for DNA Probes- based
Diagnostics (Genetic Predisposition Diagnosis) by Geographic
Region – US, Canada, Japan, Europe, Asia-Pacific (excluding
Japan), and Latin America Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2011 through
2015 (includes corresponding Graph/Chart) II-67

Table 12: World 10-Year Perspective for DNA Probes - based
Diagnostics (Genetic Predisposition Diagnosis) by Geographic
Region- Percentage Breakdown of Dollar Sales for US, Canada,
Japan, Europe, Asia–Pacific (excluding Japan) and Latin
America for Years 2003, 2008 & 2012 (includes corresponding
Graph/Chart) II-68

Table 13: World Recent Past Current & Future Analysis for DNA
Probes-based Diagnostics (Identity/Forensics Diagnosis) by
Geographic Region- US, Canada, Japan, Europe, Asia–Pacific
(excluding Japan) and Latin America Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2000 through 2010 (includes corresponding Graph/Chart) II-69

Table 14: World Long-term Projections for DNA Probes - based
Diagnostics (Identity/Forensics Diagnosis) by Geographic
Region – US, Canada, Japan, Europe, Asia-Pacific (excluding
Japan), and Latin America Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2011 through
2015 (includes corresponding Graph/Chart) II-70

Table 15: World 10-Year Perspective for DNA Probes-based
Diagnostics (Identity/Forensics Diagnosis) by Geographic
Region- Percentage Breakdown of Dollar Sales for US, Canada,
Japan, Europe, Asia–Pacific (excluding Japan) and Latin
America for Years 2003, 2008 & 2012 (includes corresponding
Graph/Chart) II-71

Table 16: World Recent Past Current & Future Analysis for DNA
Probes-based Diagnostics (Molecular HLA Testing) by
Geographic Region- US, Canada, Japan, Europe, Asia–Pacific
(excluding Japan) and Latin America Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2000 through 2010 (includes corresponding Graph/Chart) II-72

Table 17: World Long-term Projections for DNA Probes-based
Diagnostics (Molecular HLA Testing) by Geographic Region – US,
Canada, Japan, Europe, Asia-Pacific (excluding Japan), and
Latin America Markets Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2011 through 2015
(includes corresponding Graph/Chart) II-73

Table 18: World 10-Year Perspective for DNA Probes-based
Diagnostics (Molecular HLA) by Geographic Region- Percentage
Breakdown of Dollar Sales for US, Canada, Japan, Europe,
Asia–Pacific (excluding Japan) and Latin America for Years
2003, 2008 & 2012 (includes corresponding Graph/Chart) II-74

Table 19: World Recent Past Current & Future Analysis for DNA
Probes-based Diagnostics in Other Types of Diagnosis by
Geographic Region- US, Canada, Japan, Europe, Asia–Pacific
(excluding Japan) and Latin America Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2000 through 2010 (includes corresponding Graph/Chart) II-75

Table 20: World Long-term Projections for DNA Probes - based
Diagnostics in Other Types of Diagnosis by Geographic Region –
US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and
Latin America Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2011 through 2015 (includes
corresponding Graph/Chart) II-76

Table 21: World 10-Year Perspective for DNA Probes- based
Diagnostics in Other Types of Diagnosis by Geographic Region-
Percentage Breakdown of Dollar Sales for US, Canada, Japan,
Europe, Asia–Pacific (excluding Japan) and Latin America for
Years 2003, 2008 & 2012 (includes corresponding Graph/Chart) II-77


III. MARKET

1. The United States III-1
A.Market Analysis III-1
Outlook III-1
DNA-Based Diagnostic and Test Market: Progress Towards a
New Phase III-1
Rise of DNA-Based Home Testing Kits Market III-1
Product Launches III-2
Strategic Corporate Developments III-5
Key Players III-20
B.Market Analytics III-23
Table 22: US Recent Past, Current & Future Analysis for DNA
Probes-based Diagnostics by Application Area- Infectious
Diseases, Cancer, Genetic Predisposition,
Identity/Forensics, Molecular HLA Testing, and Others
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2000 through 2010 (includes
corresponding Graph/Chart) III-23

Table 23: US Long-term Projections for DNA Probes - based
Diagnostics by Application Area- Infectious Diseases,
Cancer, Genetic Predisposition, Identity / Forensics,
Molecular HLA Testing, and Others Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2011 through 2015 (includes corresponding Graph/Chart) III-24

Table 24: US 10-Year Perspective for DNA Probes-based
Diagnostics by Application Area Percentage Breakdown of
Dollar Sales for Infectious Diseases, Cancer, Genetic
Predisposition, Identity/Forensics, Molecular HLA Testing,
and Others Markets for 2003, 2008 & 2012 (includes
corresponding Graph/Chart) III-25

2. Canada III-26
A.Market Analysis III-26
Outlook III-26
Key Player III-26
Product Launch III-26
Strategic Corporate Developments III-26
B.Market Analytics III-28
Table 25: Canadian Recent Past, Current & Future Analysis
for DNA Probes-based Diagnostics by Application Area-
Infectious Diseases, Cancer, Genetic Predisposition,
Identity/Forensics, Molecular HLA Testing, and Others
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2000 through 2010 (includes
corresponding Graph/Chart) III-28

Table 26: Canadian Long-term Projections for DNA
Probes-based Diagnostics by Application Area- Infectious
Diseases, Cancer, Genetic Predisposition, Identity/
Forensics, Molecular HLA Testing, and Others Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2011 through 2015 (includes corresponding
Graph/Chart) III-29

Table 27: Canadian 10-Year Perspective for DNA Probes-based
Diagnostics by Application Area Percentage Breakdown of
Dollar Sales for Infectious Diseases, Cancer, Genetic
Predisposition, Identity/Forensics, Molecular HLA Testing,
and Others Markets for 2003, 2008 & 2012 (includes
corresponding Graph/Chart) III-30

3. Japan III-31
A.Market Analysis III-31
Outlook III-31
Strategic Corporate Development III-31
B.Market Analytics III-32
Table 28: Japanese Recent Past, Current & Future Analysis
for DNA Probes-based Diagnostics by Application Area-
Infectious Diseases, Cancer, Genetic Predisposition,
Identity/Forensics, Molecular HLA Testing, and Others
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2000 through 2010 (includes
corresponding Graph/Chart) III-32

Table 29: Japanese Long-term Projections for DNA
Probes-based Diagnostics by Application Area- Infectious
Diseases, Cancer, Genetic Predisposition, Identity/
Forensics, Molecular HLA Testing, and Others Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2011 through 2015 (includes corresponding
Graph/Chart) III-33

Table 30: Japanese 10-Year Perspective for DNA Probes-based
Diagnostics by Application Area Percentage Breakdown of
Dollar Sales for Infectious Diseases, Cancer, Genetic
Predisposition, Identity/Forensics, Molecular HLA Testing,
and Others Markets for 2003, 2008 & 2012 (includes
corresponding Graph/Chart) III-34

4. Europe III-35
A.Market Analysis III-35
Outlook III-35
Product Launches III-35
Strategic Corporate Developments III-36
B.Market Analytics III-36
Table 31: European Recent Past, Current & Future Analysis
for DNA Probes-based Diagnostics by Geographic Region –
France, Germany, Italy, UK and Rest of Europe Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2000 through 2010 (includes corresponding
Graph/Chart) III-36

Table 32: European Long-term Projections for DNA
Probes-based Diagnostics by Geographic Region – France,
Germany, Italy, UK and Rest of Europe Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2011 through 2015 (includes corresponding Graph/Chart) III-37

Table 33: European 10-Year Perspective for DNA Probes-based
Diagnostics by Geographic Region – Percentage Breakdown of
Dollar Sales for France, Germany, Italy, UK and Rest of
Europe Markets for Years 2003, 2008 & 2012 (includes
corresponding Graph/Chart) III-38

Table 34: European Recent Past, Current & Future Analysis
for DNA Probes-based Diagnostics by Application Area-
Infectious Diseases, Cancer, Genetic Predisposition,
Identity/Forensics, Molecular HLA Testing, and Others
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2000 through 2010 (includes
corresponding Graph/Chart) III-39

Table 35: European Long-term Projections for DNA
Probes-based Diagnostics by Application Area- Infectious
Diseases, Cancer, Genetic Predisposition, Identity/
Forensics, Molecular HLA Testing, and Others Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2011 through 2015 (includes corresponding
Graph/Chart) III-40

Table 36: European 10-Year Perspective for DNA Probes-based
Diagnostics by Application Area Percentage Breakdown of
Dollar Sales for Infectious Diseases, Cancer, Genetic
Predisposition, Identity/Forensics, Molecular HLA Testing,
and Others Markets for 2003, 2008 & 2012 (includes
corresponding Graph/Chart) III-41

4a. France III-42
A.Market Analysis III-42
Outlook III-42
Key Player III-42
Product Launches III-42
Strategic Corporate Developments III-43
B.Market Analytics III-45
Table 37: French Recent Past, Current & Future Analysis for
DNA Probes-based Diagnostics by Application Area- Infectious
Diseases, Cancer, Genetic Predisposition,
Identity/Forensics, Molecular HLA Testing, and Others
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2000 through 2010 (includes
corresponding Graph/Chart) III-45

Table 38: French Long-term Projections for DNA Probes-based
Diagnostics by Application Area- Infectious Diseases,
Cancer, Genetic Predisposition, Identity/Forensics,
Molecular HLA Testing, and Others Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2011 through 2015 (includes corresponding Graph/Chart) III-46

Table 39: French 10-Year Perspective for DNA Probes-based
Diagnostics by Application Area Percentage Breakdown of
Dollar Sales for Infectious Diseases, Cancer, Genetic
Predisposition, Identity/Forensics, Molecular HLA Testing,
and Others Markets for 2003, 2008 & 2012 (includes
corresponding Graph/Chart) III-47

4b. Germany III-48
A.Market Analysis III-48
Outlook III-48
Product Launch III-48
Strategic Corporate Developments III-48
B.Market Analytics III-49
Table 40: German Recent Past, Current & Future Analysis for
DNA Probes-based Diagnostics by Application Area-
Infectious Diseases, Cancer, Genetic Predisposition,
Identity/Forensics, Molecular HLA Testing, and Others
Markets Independently Analyzed with Annual Sales Figures
in US$ Million for Years 2000 through 2010 (includes
corresponding Graph/Chart) III-49

Table 41: German Long-term Projections for DNA Probes-based
Diagnostics by Application Area- Infectious Diseases, Cancer,
Genetic Predisposition, Identity/ Forensics, Molecular HLA
Testing, and Others Markets Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2011 through 2015
(includes corresponding Graph/Chart) III-50

Table 42: German 10-Year Perspective for DNA Probes-based
Diagnostics by Application Area Percentage Breakdown of Dollar
Sales for Infectious Diseases, Cancer, Genetic
Predisposition, Identity/Forensics, Molecular HLA Testing, and
Others Markets for 2003, 2008 & 2012 (includes corresponding
Graph/Chart) III-51

4c. Italy III-52
A.Market Analysis III-52
Strategic Corporate Development III-52
B.Market Analytics III-53
Table 43: Italian Recent Past, Current & Future Analysis for
DNA Probes-based Diagnostics by Application Area - Infectious
Diseases, Cancer, Genetic Predisposition, Identity/Forensics,
Molecular HLA Testing, and Others Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2000 through 2010 (includes corresponding Graph/Chart) III-53

Table 44: Italian Long-term Projections for DNA Probes-based
Diagnostics by Application Area- Infectious Diseases, Cancer,
Genetic Predisposition, Identity / Forensics, Molecular HLA
Testing, and Others Markets Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2011 through 2015
(includes corresponding Graph/Chart) III-54

Table 45: Italian 10-Year Perspective for DNA Probes-based
Diagnostics by Application Area- Percentage Breakdown of
Dollar Sales for Infectious Diseases, Cancer, Genetic
Predisposition, Identity/Forensics, Molecular HLA Testing, and
Others Markets for 2003, 2008 & 2012 (includes corresponding
Graph/Chart) III-55

4d. The United Kingdom III-56
A.Market Analysis III-56
Outlook III-56
Strategic Corporate Development III-56
B.Market Analytics III-57
Table 46: UK Recent Past, Current & Future Analysis for DNA
Probes-based Diagnostics by Application Area- Infectious
Diseases, Cancer, Genetic Predisposition, Identity/Forensics,
Molecular HLA Testing, and Others Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2000 through 2010 (includes corresponding Graph/Chart) III-57

Table 47: UK Long-term Projections for DNA Probes - based
Diagnostics by Application Area- Infectious Diseases, Cancer,
Genetic Predisposition, Identity/Forensics, Molecular HLA
Testing, and Others Markets Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2011 through 2015
(includes corresponding Graph/Chart) III-58

Table 48: UK 10-Year Perspective for DNA Probes- based
Diagnostics by Application Area- Percentage Breakdown of
Dollar Sales for Infectious Diseases, Cancer, Genetic
Predisposition, Identity/Forensics, Molecular HLA Testing,
and Others Markets for 2003, 2008 & 2012 (includes
corresponding Graph/Chart) III-59

4e. Rest of Europe III-60
A.Market Analysis III-60
Outlook III-60
Product Launches III-60
Strategic Corporate Developments III-61
Key Player III-62
B.Market Analytics III-63
Table 49: Rest of Europe Recent Past, Current & Future
Analysis for DNA Probes-based Diagnostics by Application Area
- Infectious Diseases, Cancer, Genetic Predisposition,
Identity/Forensics, Molecular HLA Testing, and Others Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2000 through 2010 (includes corresponding
Graph/Chart) III-63

Table 50: Rest of Europe Long-term Projections for DNA
Probes-based Diagnostics by Application Area- Infectious
Diseases, Cancer, Genetic Predisposition, Identity/Forensics,
Molecular HLA Testing, and Others Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2011 through 2015 (includes corresponding Graph/Chart) III-64

Table 51: Rest of Europe 10-Year Perspective for DNA
Probes-based Diagnostics by Application Area- Percentage
Breakdown of Dollar Sales for Infectious Diseases, Cancer,
Genetic Predisposition, Identity/Forensics, Molecular HLA
Testing, and Others Markets for 2003, 2008 & 2012 (includes
corresponding Graph/Chart) III-65

5. Asia-Pacific III-66
A.Market Analysis III-66
Outlook III-66
Strategic Corporate Development III-66
B.Market Analytics III-68
Table 52: Asia-Pacific Recent Past, Current & Future Analysis
for DNA Probes-based Diagnostics by Application Area-
Infectious Diseases, Cancer, Genetic Predisposition,
Identity/Forensics, Molecular HLA Testing, and Others Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2000 through 2010 (includes corresponding
Graph/Chart) III-68

Table 53: Asia-Pacific Long-term Projections for DNA
Probes-based Diagnostics by Application Area- Infectious
Diseases, Cancer, Genetic Predisposition, Identity/Forensics,
Molecular HLA Testing, and Others Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2011 through 2015 (includes corresponding Graph/Chart) III-69

Table 54: Asia-Pacific 10-Year Perspective for DNA
Probes-based Diagnostics by Application Area- Percentage
Breakdown of Dollar Sales for Infectious Diseases, Cancer,
Genetic Predisposition, dentity/ Forensics, Molecular HLA
Testing, and Others Markets for 2003, 2008 & 2012 (includes
corresponding Graph/Chart) III-70

6. Latin America III-71
Market Analysis III-71
Table 55: Latin American Recent Past, Current & Future
Analysis for DNA Probes-based Diagnostics by Application
Area- Infectious Diseases, Cancer, Genetic Predisposition,
Identity/Forensics, Molecular HLA Testing, and Others Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2000 through 2010 (includes corresponding
Graph/Chart) III-71

Table 56: Latin America Long-term Projections for DNA
Probes-based Diagnostics by Application Area- Infectious
Diseases, Cancer, Genetic Predisposition, Identity/Forensics,
Molecular HLA Testing, and Others Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2011 through 2015 (includes corresponding Graph/Chart) III-72

Table 57: Latin American 10-Year Perspective for DNA
Probes-based Diagnostics by Application Area- Percentage
Breakdown of Dollar Sales for Infectious Diseases, Cancer,
Genetic Predisposition, dentity/ Forensics, Molecular HLA
Testing, and Others Markets for 2003, 2008 & 2012 (includes
corresponding Graph/Chart) III-73


IV. COMPETITIVE LANDSCAPE


-Abbott Laboratories (USA)
-Affymetrix, Inc (USA)
-Applied Biosystems Group (USA)
-Bayer Healthcare-Beacon Diagnostics, Inc (USA)
-Beckman Coulter, Inc (USA)
-Becton Dickinson & Company (USA)
-BioGenex Laboratories, Inc (USA)
-BioMerieux SA (France)
-Biotest AG (Germany)
-Calypte Biomedical Corporation (USA)
-Celltech Group Plc (UK)
-Chiron Corporation (USA)
-Cytogen Corporation (USA)
-Dade Behring, Inc (USA)
-Diasorin, Inc (USA)
-Digene Corporation (USA)
-Enzo Life Sciences, Inc (USA)
-Exonix, Inc (USA)
-Gen-Probe, Inc (USA)
-Genzyme Corporation (USA)
-Home Access Health Corporation (USA)
-ID Biomedical Corporation (Canada)
-Idaho Technology, Inc (USA)
-Idexx Laboratories, Inc (USA)
-Immunovision, Inc (USA)
-Incyte Corporation (USA)
-Innogenetics NV (Belgium)
-Myriad Genetics, Inc (USA)
-Nuvelo, Inc (USA)
-Peninsula Laboratories, Inc (A Bachem Group Co)
(USA)
-PerkinElmer, Inc (USA)
-Promega Corporation (USA)
-Qbiogene, Inc (USA)
-Roche Diagnostics (Switzerland)
AG (Switzerland)
-Serologicals Corporation (USA)
-Sigma-Genosys Ltd (UK)
-Signet Laboratories, Inc (USA)
-Therion International, LLC (USA)
-TM Bioscience Corporation (Canada)
-Ventana Medical Systems, Inc (USA)
-Veridex LLC (USA)
-Virologic, Inc (USA)